GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and cancer immunotherapies, today announced that its Chairman and CEO, David Dodd, will present at the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference (NobleCon21) on December 3, 2025, at 3:00 pm ET in Boca Raton, Florida. The presentation will provide a corporate update, covering the company's lead programs, including GEO-CM04S1, a next-generation COVID-19 vaccine, and Gedeptin®, a novel oncolytic therapy for head and neck cancers.
The announcement is significant as it comes amid ongoing Phase 2 clinical trials for GEO-CM04S1, which targets immunocompromised patients and those with chronic lymphocytic leukemia (CLL), as well as healthy individuals seeking a more durable booster than mRNA vaccines. GeoVax also recently completed a Phase 1/2 trial for Gedeptin® in advanced head and neck cancers and is advancing a vaccine against Mpox and smallpox, with regulatory guidance to skip early-phase trials and move directly to Phase 3. These developments underscore the company's potential to address critical unmet medical needs.
Interested parties can attend the conference at a discounted rate by registering with the code GOVXNOBLECON. A webcast of the presentation will be available the following day on the Noble Capital Markets conference website (www.nobleconference.com) and on Channelchek (www.channelchek.com), the investor portal created by Noble. The webcast will be archived for 90 days. Senior GeoVax management will also host one-on-one meetings with registered attendees.
GeoVax's strong intellectual property portfolio and worldwide rights to its technologies position it favorably in the competitive biotech landscape. The company's focus on next-generation vaccines and cancer therapies highlights its commitment to innovation, and the presentation at NobleCon21 offers investors an opportunity to gain insights into its strategic direction. For more information about GeoVax and its clinical trials, visit www.geovax.com.
